News >

Tracing Treatment Strategies in Early-Stage HR+/HER2- Breast Cancer

Caroline Seymour
Published: Wednesday, Oct 16, 2019

Gretchen G. Kimmick, MD, MS

Gretchen G. Kimmick, MD, MS

The management of patients with early-stage hormone receptor (HR)–positive, HER2-negative breast cancer is changing, and in February 2019, the National Comprehensive Cancer Network guidelines were updated to reflect the increasing importance of a patient’s risk of recurrence in guiding treatment strategies.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication